XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Interim Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Expenses:        
Research and development $ 484,306 $ 1,176,337 $ 1,504,124 $ 1,880,795
General and administrative 1,154,580 1,044,137 2,033,451 2,197,108
Loss from operations (1,638,886) (2,220,474) (3,537,575) (4,077,903)
Other income:        
Reimbursement grant income 52,268 304,002 353,463 424,836
Interest income 265 43,193 1,931 104,159
Misc other income 0 14,766 0 14,766
Foreign exchange (loss) (3,295) (2,018) (24,720) (4,840)
Nonoperating Income (Expense) 49,238 359,943 330,674 538,921
Loss before income taxes (1,589,648) (1,860,531) (3,206,901) (3,538,982)
Income tax expense 800 800 800 800
Net loss (1,590,448) (1,861,331) (3,207,701) (3,539,782)
Exchange differences on translation (63,731) (11,183) (45,075) (11,755)
Net comprehensive loss $ (1,654,179) $ (1,872,514) $ (3,252,776) $ (3,551,537)
Weighted average number of common shares (in shares) 5,305,763 3,192,688 4,314,676 3,160,179
Loss per common share - basic and diluted (in dollars per share) $ (0.3) $ (0.58) $ (0.74) $ (1.12)